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Kakall ZM, Kavurma MM, Cohen EM, Howe PR, Nedoboy
PE, Pilowsky PM. Repetitive hypoglycemia reduces activation of
glucose-responsive neurons in C1 and C3 medullary brain regions to
subsequent hypoglycemia. Am J Physiol Endocrinol Metab 317:
E388–E398, 2019. First published April 23, 2019; doi:10.1152/
ajpendo.00051.2019.—The impaired ability of the autonomic nervous
system to respond to hypoglycemia is termed “hypoglycemia-associ-
ated autonomic failure” (HAAF). This life-threatening phenomenon
results from at least two recent episodes of hypoglycemia, but the
pathology underpinning HAAF remains largely unknown. Although
naloxone appears to improve hypoglycemia counterregulation under
controlled conditions, hypoglycemia prevention remains the current
mainstay therapy for HAAF. Epinephrine-synthesizing neurons in the
rostroventrolateral (C1) and dorsomedial (C3) medulla project to the
subset of sympathetic preganglionic neurons that regulate peripheral
epinephrine release. Here we determined whether or not C1 and C3
neuronal activation is impaired in HAAF and whether or not 1 wk of
hypoglycemia prevention or treatment with naloxone could restore C1
and C3 neuronal activation and improve HAAF. Twenty male
Sprague-Dawley rats (250–300 g) were used. Plasma epinephrine
levels were significantly increased after a single episode of hypogly-
cemia (n  4; 5,438  783 pg/ml vs. control 193  27 pg/ml, P 
0.05). Repeated hypoglycemia significantly reduced the plasma epi-
nephrine response to subsequent hypoglycemia (n  4; 2,179  220
pg/ml vs. 5,438  783 pg/ml, P  0.05). Activation of medullary C1
(n  4; 50  5% vs. control 3  1%, P  0.05) and C3 (n  4;
45  5% vs. control 4  1%, P  0.05) neurons was significantly
increased after a single episode of hypoglycemia. Activation of C1
(n  4; 12  3%, P  0.05) and C3 (n  4; 19  5%, P  0.05)
neurons was significantly reduced in the HAAF groups. Hypoglyce-
mia prevention or treatment with naloxone did not restore the plasma
epinephrine response or C1 and C3 neuronal activation. Thus repeated
hypoglycemia reduced the activation of C1 and C3 neurons mediating
adrenal medullary responses to subsequent bouts of hypoglycemia.
catecholaminergic neurons; dorsomedial medulla; epinephrine; HAAF;
ventrolateral medulla
INTRODUCTION
Type 1 diabetic (T1D) patients are at increased risk of
developing life-threatening hypoglycemia due to the imperfect
regulation of exogenously administered insulin. The sympa-
thoadrenal response that restores blood glucose (BG) levels is
weakened after a preceding episode of hypoglycemia. This
eventually leads to a blunted counterregulatory response oc-
curring at progressively lower BG levels. This phenomenon is
termed “hypoglycemia-associated autonomic failure” (HAAF).
Both the sympathoadrenal counterregulatory response and the
behavioral adaptation to hypoglycemia are initiated at lower
BG levels in HAAF. Together with reduced neurogenic and
neuroglycopenic symptoms of hypoglycemia, HAAF signifi-
cantly contributes to the development of hypoglycemia un-
awareness. Unawareness of hypoglycemia is a significant bur-
den on the health care system worldwide, as well as a major
cause of recurrent morbidity and mortality in patients with
diabetes (5, 14, 62).
Glucagon and epinephrine are important counterregulatory
hormones that are released after hypoglycemia in healthy
humans. The epinephrine response following sympathetic neu-
ral activation is critical in T1D patients and is due to islet cell
failure and the subsequent inability to increase glucagon levels
after hypoglycemia (3, 15). Thus a better understanding of the
pathophysiology underlying HAAF is critical to reducing the
incidence of severe hypoglycemia by ensuring an adequate
plasma epinephrine response. Current preventative approaches
to reduce the incidence of severe hypoglycemia require the
meticulous management of BG levels (11, 12). Clinical studies
in which hypoglycemia is induced with a hyperinsulinemic-
hypoglycemic clamp preparation show that coinfusion of nal-
oxone, an opioid receptor antagonist, improves epinephrine
release and endogenous glucose production in both healthy and
T1D subjects (4, 27, 42, 57). Despite the use of hypoglycemia
prevention and the promise of naloxone therapy, the mecha-
nisms whereby epinephrine secretion and glucose recovery
appear to be improved after these treatments remain unknown.
Hypoglycemia-induced activation of the sympathoadrenal
axis results in the release of epinephrine from chromaffin cells
(37). Adrenergic neurons of the rostroventrolateral (C1) and
dorsomedial (C3) medulla oblongata contain axonal projec-
tions to adrenal sympathetic preganglionic neurons (31, 37, 40,
51). Furthermore, hypoglycemia- or glucoprivation-induced
activation of C1 and C3 neurons results in epinephrine release
from chromaffin cells located in the adrenal medulla (29, 37,
44, 45, 49). These findings suggest that after hypoglycemia a
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positive association exists between the activation state of
medullary catecholaminergic (C1 and C3) neurons and down-
stream epinephrine secretion. Therefore, the improvements in
epinephrine release following hypoglycemia prevention or nal-
oxone therapy may be due to the restoration of C1 and C3
neuronal activity.
In the present study, we used a rodent model of HAAF
(adapted from Ref. 48) to determine whether repeated insulin-
induced hypoglycemia reduced the activation of C1 and C3
medullary neurons. Our specific aims were to determine
whether 1) a 3-day repeated hypoglycemia protocol reduces C1
and C3 neuronal activation and 2) a hypoglycemia prevention
protocol or 3) injection of naloxone during antecedent hypo-
glycemia in HAAF rats can restore C1 and C3 neuronal
activation and epinephrine release after subsequent hypogly-
cemia.
METHODS
Animal procedures. All experiments were conducted in accordance
with the Australian Code of Practice for the Care and Use of Animals
for Scientific Purposes (New South Wales: Animal Research Act
1985), certified by the National Health and Medical Research Council
of Australia. The protocol for this study was reviewed and approved
by the Sydney Local Health District Animal Welfare Committee
(protocol no. 2018/014). Unfasted male Sprague-Dawley rats (n  20)
weighing between 250 and 300 g were used in this study. Animals
were fed ad libitum with a standard irradiated rat diet (Specialty
Feeds) and autoclaved reverse-osmosis water.
Blood glucose analysis. Rats were removed from their home cages
on the morning of each experiment for the purpose of BG analysis and
intraperitoneal drug injections. Rats were carefully placed in a re-
straint before BG levels were measured in order to prevent handling
stress. BG levels were subsequently measured with a glucometer
(Accu-Chek Performa) from a tail vein nick. If dilation of the tail vein
was required to enhance vessel visibility, the tail was briefly placed in
a warm water bath (~30°C) to enhance blood flow to the required area.
Rats were removed from the restraint immediately afterward and
carefully prepared for intraperitoneal injections. BG levels were
measured once before drug administration and finally 2 h after
injection.
Animal experiments. Figure 1 provides a detailed description of the
protocols. Rats were separated into groups receiving intraperitoneal
injections of saline, insulin (5 U/kg), and/or naloxone (1 mg/kg).
Injections were performed once daily over 3 days in each animal (n 
4 animals/group). The injection groups were as follows: control
(volume-matched saline injections once daily for 3 days), single
hypoglycemia (saline days 1 and 2, insulin day 3), repeated hypogly-
cemia-HAAF (insulin days 1, 2, and 3), hypoglycemia prevention
(insulin days 1, 2, and 9), and naloxone treated (insulin followed by
naloxone injection after the final glucose measurement 2 h after
injection on days 1 and 2; only insulin was injected on day 3).
On the final day, after the BG measurement at 2 h, rats were
injected with a lethal dose of pentobarbital sodium (1 ml of 65 mg/kg).
Cardiac blood was collected from the left ventricle and stored in an
EDTA tube. Rats were then transcardially perfused with 400 ml of
phosphate-buffered saline (PBS; 10 mM sodium phosphate buffer in
0.9% sodium chloride at pH 7.4) followed by 400 ml of 10% neutral
buffered formalin (Sigma-Aldrich, Darmstadt, Germany). Brain tissue
was postfixed at room temperature for 24 h, placed in PBS treated
with merthiolate, and stored at 4°C until required. Brain stems were
separated and cut into 40-m coronal sections with a vibrating
microtome (Leica VT1200). Sections were collected sequentially into
five individual pots containing cryoprotectant and stored at 20°C
until required for immunohistochemistry.
Epinephrine ELISA. Blood samples were centrifuged down at a
speed of 4,750 rpm at 4°C for 10 min, and the plasma was collected
and stored at 80°C for biochemical analysis. Fifty-microliter sam-
ples were used from each group, and plasma epinephrine concentra-
tions were measured with a BA E-5100 Adrenaline Research ELISA
kit (Taylor Biomedical).
Immunohistochemical analysis of Fos and phenylethanolamine
-N-methyltransferase. Before the addition of antibodies, brain stem
sections were washed (3  30 min) with PBS containing 0.3% Triton
X. Sections were incubated with 100 l of donkey serum (Sigma-
Aldrich, catalog no. D9663-10ML), 900 l of PBS-Tris buffer con-
taining 0.1% merthiolate and 0.3% Triton X-100, and 1 l of the
primary antibodies phenylethanolamine-N-methyltransferase (PNMT,
1:1,000 dilution, rabbit polyclonal; produced by P. R. Howe) and Fos
(1:1,000 dilution, guinea pig polyclonal; Synaptic Systems, catalog.
no. 226004) for 72 h at 4°C on an orbital shaker. After this, sections
were once again washed (3  30 min) with PBS before the addition
of secondary antibodies. The PNMT antibody was validated for
specificity by P. R. Howe (20). This was followed by the addition of
980 l of PBS-Tris buffer containing 0.1% merthiolate, 20 l of
donkey serum, and 4 l of the secondary antibodies anti-rabbit Cy3
(1:500 dilution; Jackson Immunoresearch, catalog no. 711-166-152)
for the detection of PNMT and anti-guinea pig Alexa Fluor 488 (1:500
dilution; Jackson Immunoresearch, catalog no. 706-546148) for the
detection of Fos. All sections were protected from light and placed on
an orbital shaker at room temperature for 24 h. Finally, the sections
were washed once again with PBS (3  30 min) and mounted on glass
slides. Mounted sections were allowed to dry before being cover-
slipped with ProLong Diamond antifade mountant (ThermoFisher
Scientific) and sealed with clear nail polish.
Microscopy. Immunofluorescent (20 magnification) images for
the cell count analysis were captured with a Zeiss Axio Scan Z1 slide
scanner microscope. Exposure time settings remained consistent for
all sections at the time of imaging. Contrast and brightness of the
resulting images were adjusted to maximize our ability to count cells
with minimal background interference. Slides were coded during
microscopy, and all analysis was performed under “blinded” condi-
tions to avoid experimenter bias. For illustrative purposes, photomi-
crographs (40 magnification) were obtained with a Zeiss Axio
Imager Z2.
Data analysis and statistics. The total numbers of PNMT and
double-stained FosPNMT cells in the C1 (bregma level 12.48 to
12.24) and C3 (bregma level 12.48 to 12.24) regions were
quantified with Zen 2.3 (Blue edition). A rectangular region of interest
was placed bilaterally in the C1 region (5,500  3,700 m) and in the
C3 region (7,000  4,000 m). In each treatment group (n  4
animals/group), the total numbers of cells in two sections per region
from each animal were recorded. The average number in each group
was used to calculate the total number of activated C1 and C3
neurons(expressed as % FosPNMT/PNMT). Comparisons were
made with one- or two-way ANOVA as appropriate. Statistical
analysis was performed with GraphPad Prism software (v7.02). Mul-
tiple comparisons were made with the post hoc Holm-Šidák test where
appropriate.
RESULTS
Insulin-induced hypoglycemia protocols. Intraperitoneal in-
jections of insulin (5 U/kg) were administered to induce hy-
poglycemia once daily for 3 days in the HAAF treatment
groups (Fig. 1). Insulin was injected on day 3 only in the
single-hypoglycemia group. Control rats were provided with
an intraperitoneal injection of volume-matched saline. The
threshold for hypoglycemia was BG  3.9 mM. The saline-
treated control group (n  4) remained normoglycemic on all
3 days (Fig. 1A). In the single-hypoglycemia group (n  4),
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BG levels after saline injections on days 1 and 2 remained at
normoglycemia, whereas insulin significantly reduced BG lev-
els from 7.5  0.3 mM to 2.8  0.2 mM on day 3 (Fig. 1B). In
the repeated-hypoglycemia group (n  4), BG levels 2 h after
injection of insulin were significantly reduced from the
matched preinjection time points (Fig. 1C): 3.1  0.1 mM (day
1), 2.8  0.2 mM (day 2), and 2.7  0.1 mM (day 3). In the
1-wk hypoglycemia prevention group (n  4), BG levels after
insulin were significantly reduced to 3.2  0.3 mM (day 1),
3.3  0.3 mM (day 2), and 3.0  0.2 mM (day 9) (Fig. 1D). In
the naloxone-treated group (n  4), BG levels after insulin
were significantly reduced to 2.8  0.2 mM (day 1), 3.0  0.2
mM (day 2), and 3.2  0.2 mM (day 3) (Fig. 1E).
Antecedent insulin-induced hypoglycemia reduces plasma
epinephrine levels after subsequent hypoglycemia. Plasma epi-
nephrine levels were measured by ELISA to determine how the
sympathoadrenal response to hypoglycemia was affected in
each treatment group (Fig. 2). Blood was collected by
cardiac puncture 2 h after injection on the final day of
treatment in all animals. Plasma epinephrine levels signifi-
cantly increased in the single-hypoglycemia group com-
pared with control (5,438  783 pg/ml vs. control 193  27
pg/ml; Fig. 2). Repeated hypoglycemia significantly reduced
the plasma epinephrine response to subsequent hypoglycemia
(2,179  220 pg/ml vs. single hypoglycemia 5,438  783 pg/
ml; Fig. 2). In the HAAF rats, hypoglycemia prevention or
Fig. 1. Insulin-induced hypoglycemia protocols (inset) and blood glucose levels in all treatment groups: grouped data (n  4 animals/group) indicating blood
glucose (BG) levels in groups treated with insulin (I; 5 U/kg) or saline control (S). BG levels were measured before injections and 2 h after injections.
Hypoglycemia was achieved if BG  3.9 mM. In the control group (A), animals were injected with volume-matched 0.9% saline once daily for 3 days. In the
single-hypoglycemia (hypo) group (B), saline was injected on days 1 and 2, followed by insulin on day 3. In the repeated-hypo group (C), insulin was injected
on all days. In the hypo prevention group (D), insulin was injected on days 1, 2, and 9. In the naloxone (N)-treated group (E), insulin was injected on days 1,
2, and 3, followed by intraperitoneal injection of naloxone (1 mg/kg) after the 2-h BG levels were recorded on days 1 and 2. Data are means  SE. Statistical
significance was determined by 1-way ANOVA and multiple-comparison analysis with a Holm-Šidák correction. ****P  0.0001, significantly different from
all other groups.
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naloxone treatment failed to restore the plasma epinephrine
response to subsequent hypoglycemia.
Antecedent insulin-induced hypoglycemia reduces activa-
tion of adrenergic neurons in medullary C1 and C3 nuclei after
subsequent hypoglycemia. The total number of Fos and PNMT
dually immunoreactive neurons in the C1 and C3 medullary
regions was quantified in all treatment groups (Figs. 3–6). In
the C1 region, repeated saline injections did not significantly
increase Fos expression (Fig 3A, Fig. 4A, and Fig. 7A). A
single episode of hypoglycemia significantly increased the %
FosPNMT/PNMT neurons compared with all other treat-
ment groups (50  5% vs. control 3  1%; Fig. 3B, Fig. 4B,
and Fig. 7A). Furthermore, repeated hypoglycemia signifi-
cantly reduced the activation of these neurons after subsequent
hypoglycemia (12  3% vs. single hypoglycemia 50  5%;
Fig. 3C, Fig. 4C, and Fig. 7A). Hypoglycemia prevention (Fig.
3D, Fig. 4D, and Fig. 7A) or naloxone treatment (Fig. 3E, Fig.
4E, and Fig. 7A) did not restore C1 neuronal activation.
In the C3 region, repeated saline injections did not signifi-
cantly increase Fos expression (Fig. 5A, Fig. 6A, and Fig. 7B).
A single episode of hypoglycemia significantly increased the %
FosPNMT/PNMT neurons compared with saline control
(45  5% vs. control 4  1%; Fig. 5B, Fig. 6B, and Fig. 7B).
Repeated hypoglycemia significantly reduced the activation
of adrenergic C3 neurons after subsequent hypoglycemia
(19  5% vs. single hypoglycemia 45  5%; Fig. 5C, Fig. 6C,
and Fig. 7B). Hypoglycemia prevention (Fig. 5D, Fig. 6D, and
Fig. 7B) or naloxone treatment (Fig. 5E, Fig. 6E, and Fig. 7B)
did not restore C3 neuronal activation.
A direct correlation between plasma epinephrine levels and
C1 or C3 neuronal activation was observed (Fig. 8), suggesting
that increased C1 (Fig. 8A; R2  0.7692) and C3 (Fig. 8B;
R2  0.4352) neuronal activation is closely correlated with
increasing plasma epinephrine levels.
Repeated hypoglycemia does not alter neuronal PNMT ex-
pression in medullary C1 and C3 regions. The total numbers of
PNMT neurons in the C1 and C3 regions were quantified.
These values were not significantly different across all treat-
ment groups (Fig. 9).
DISCUSSION
The novel finding of the present study is that in HAAF
activation of C1 and C3 glucose-responsive neurons is reduced
after two episodes of antecedent hypoglycemia. Plasma epi-
nephrine release and the sympathoadrenal response to hypo-
glycemia were also reduced in HAAF rats. Interestingly, the
hypoglycemia prevention protocol (Fig. 1) and injection of
naloxone during antecedent hypoglycemia had little effect on
the activity of C1 and C3 neurons. Only 50% of the expected
downstream sympathoadrenal response to hypoglycemia was
recovered, which was comparable to the repeated-hypoglyce-
mia-HAAF treatment group (see Fig. 2).
Hypoglycemia initiates the activation of hypothalamic and
medullary pathways that enhance pancreatic glucagon and
adrenal medullary epinephrine secretion (24, 25, 58–60). Re-
cently, Senthilkumaran et al. (49) used a diaminobenzidine
staining method to demonstrate the presence of glucose-re-
sponsive neurons in the C1 and C3 medullary regions as well
as in the chromaffin cells of the adrenal medulla. Similar
diaminobenzidine staining methodology revealed that Fos ex-
pression is also present in the C1 and C3 regions after systemic
2-deoxyglucose (2-DG)-induced glucoprivation (41, 45). Re-
peated 2-DG-induced glucoprivation significantly reduced Fos
expression in the C1 and C3 medullary regions (47). Plasma
epinephrine levels were not reported in the study by Sanders
and Ritter (47), but the hyperglycemic effect of 2-DG was
abolished in the repeated 2-DG-treated group. It is worth
noting that 2-DG is a glucose analog that competes for glucose
uptake and is therefore a potent inhibitor of glycolysis. The
systemic administration of 2-DG produces hyperglycemia and
initiates the sympathoadrenal counterregulatory response caus-
ing both epinephrine and glucagon to be released peripherally
(21–24). Although a similar subset of medullary neurons is
activated after either 2-DG or insulin injections, the physio-
logical mechanisms underlying HAAF must be determined
with models of insulin-induced hypoglycemia, rather than
glucoprivation, to maintain biological relevance. The present
study is the first to link reduced activation of C1 and C3
medullary neurons in a rodent model of insulin-induced
HAAF. We believe the activation of C1 and C3 neurons is
required for downstream epinephrine release, and any treat-
ments that serve to improve activation of these medullary
neurons will subsequently restore the downstream sympathoa-
drenal response (Fig. 8). The central pathway resulting in
downstream activation of C1 and C3 neurons after hypoglyce-
mia remains unknown, but numerous studies suggest that the
activation of glucose-inhibited neurons in the hypothalamic
ventromedial nucleus and perifornical nucleus may trigger the
counterregulatory response to hypoglycemia (24, 25, 46, 53,
59, 63).
Fig. 2. Antecedent insulin-induced hypoglycemia reduces plasma epinephrine
levels after subsequent hypoglycemia: grouped data indicating plasma epi-
nephrine levels measured from blood samples collected on the final day of
injections from each animal. Plasma epinephrine levels were not affected in
saline-treated control rats (n  4). In the single-hypoglycemia (hypo) group, 1
episode of hypoglycemia significantly increased plasma epinephrine levels
(n  4). In the repeated-hypo group, plasma epinephrine levels after the last
episode of hypoglycemia were significantly reduced compared with the single-
hypo group (n  4). Plasma epinephrine levels remained at levels similar to the
repeated-hypo group after 1 wk of hypoglycemia prevention (n  4) or
naloxone treatment (n  4). Data are means  SE. Statistical significance was
determined by 1-way ANOVA and multiple-comparison analysis with a
Holm-Šidák correction. *P  0.05, ***P  0.001, significantly different from
all other groups.
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Intensive insulin therapy enables a profound reduction in
microvascular complications (neuropathy, retinopathy, and ne-
phropathy) commonly caused by T1D (8, 64). The imperfect
pharmacokinetic and pharmacodynamic regulation of insulin
requires careful consideration when administering the drug for
treatment. A single episode of antecedent hypoglycemia can
reduce the sympathoadrenal response to subsequent hypogly-
cemia, with repeated episodes of hypoglycemia leading to the
development of HAAF (50). Established HAAF, together with
impaired awareness of hypoglycemia, increases the risk of
developing severe hypoglycemia, potentially leading to coma
or death (6, 7). Improvement in glycemic control is achieved
clinically by regular monitoring of blood glucose levels to-
gether with structured education programs aiming to reduce the
incidence of mild and severe hypoglycemic events (9, 19).
Here we tested the hypothesis that hypoglycemia prevention
would restore the sympathoadrenal response to hypoglycemia
as well as C1 and C3 neuronal activation in our model of
HAAF. Our rationale was based on clinical findings indicating
that both the symptomatic and epinephrine responses were
restored by ~50% in T1D patients after 2 wk of meticulous
glycemic management (11). Despite the healthy Sprague-Daw-
ley background of our HAAF rats, delayed induction of the
final hypoglycemia by 1 wk was insufficient to restore an
adequate neuronal, or epinephrine, response to subsequent
hypoglycemia.
Naloxone is a rapidly acting opioid antagonist that crosses
the blood-brain barrier and is commonly used to reverse
opioid-induced overdose. It is a nonselective competitive an-
tagonist at all central and peripherally located opioid receptors,
with a particularly high affinity for the -receptor subtype.
Coinfusion of insulin and naloxone during antecedent hypo-
glycemia in human studies improved the epinephrine response,
endogenous glucose production, and hypoglycemia symptom
scores after subsequent hypoglycemia (27, 32, 42, 57). Not-
withstanding clinical studies demonstrating the potential of
Fig. 3. Representative images (20) of treated C1 sections depicting Fos and phenylethanolamine-N-methyltransferase (PNMT) immunolabeling. A–E:
representative photomicrographs (20 magnification) of Fos (green) and PNMT (red) immunolabeling in the C1 medullary region of rat tissue (n  4
animals/group). Cy3 fluorescence is pseudocolored red, and Alexa Fluor 488 is represented in green. Images represent staining in control (A), single-
hypoglycemia (hypo) (B), repeated-hypo (C), hypo prevention (D), and naloxone-treated (E) animal tissue. Overlapping FosPNMT cells are indicated by
arrows. F: bregma levels used for analysis. AmbC, ambiguus nucleus, compact part; Bo, Bötzinger complex; Sp5, spinal trigeminal nucleus; 4V, fourth ventricle.
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naloxone in improving the sympathoadrenal and symptomatic
response to hypoglycemia, the exact mechanisms mediating
this effect remain unknown. Conflicting findings in rodent
models of HAAF indicate that intraperitoneal injection of 5
mg/kg naloxone 15 min before 10 U/kg insulin injections did
not restore plasma epinephrine levels after subsequent hypo-
glycemia (48). Our measurements of plasma epinephrine are
comparable to those of Senthilkumaran and Bobrovskaya (48)
despite the fact that we lowered the dose of naloxone to 1
mg/kg to prevent any potential nonspecific effects (13). We
also injected naloxone 2 h after insulin-induced hypoglycemia
to determine whether a more physiologically relevant time
frame of administration would recover the epinephrine re-
sponse. Coadministration of naloxone and insulin is yet to be
tested in animal models of HAAF, as the ideal option would be
to select a drug that would be effective for use during estab-
lished hypoglycemia.
In a controlled clinical study by Leu et al. (27), the epineph-
rine response in nondiabetic humans was reduced after recur-
rent hypoglycemia, although these individuals possessed an
intact glucagon response. Furthermore, the epinephrine re-
sponse was successfully restored in these healthy subjects with
continuous naloxone infusions, despite their ability to mount a
sufficient glucagon response. On the other hand, the glucagon
response to hypoglycemia is completely lost in T1D patients
(57), and after recurrent hypoglycemia the impaired plasma
epinephrine response is improved with naloxone infusions. In
light of this evidence, although measurements of plasma glu-
cagon would be informative, we do not believe an intact
glucagon response would have affected the ability of naloxone
to restore the epinephrine response.
Central activation of neurons in the medulla oblongata may
regulate improvements in adrenal medullary chromaffin cell
catecholamine synthesis and secretion. Although we did not
quantify adrenal medullary chromaffin cell responsiveness,
earlier studies have shown that naloxone, but not methylnal-
trexone (another broad-spectrum opioid antagonist that does
not cross the blood-brain barrier), significantly improves the
levels of tyrosine hydroxylase phosphorylation of Ser31 and
Ser40 in the adrenal gland of HAAF rats (48). Together, these
results indicate that the pathway increasing tyrosine hydroxy-
lase phosphorylation in the adrenal gland after HAAF may be
mediated by slight improvements in central neuronal respon-
siveness following naloxone treatment that remain undetected
by our method of assessment. The improvement we observed
was not significant and did not restore plasma epinephrine
release in the present study.
The development of a peripheral defect at the level of
epinephrine-secreting chromaffin cells after recurrent hypogly-
cemia contributes to the impaired counterregulatory secretion
of epinephrine (28, 38). Ma et al. (28) showed that in a rodent
model of HAAF defects existed in the adrenal gland but not in
the downstream hepatic components of the counterregulatory
response. These results suggest that impaired sympathetic
efferent neuronal signaling causes reduced activation of epi-
nephrine-secreting cells in the adrenal gland, since cell death
was not observed in the adrenal gland (28). Although their
results did not reach significance, Sivitz et al. (52) showed that
adrenal sympathetic nerve activity was reduced in HAAF rats
exposed to subsequent hypoglycemia. These observations do
not exclude the possibility that there is also impaired activation
of C1 and C3 neurons after repeated hypoglycemia. The
Fig. 4. Representative images (40) of treated C1 sections depicting Fos and phenylethanolamine-N-methyltransferase (PNMT) immunolabeling: representative
photomicrographs (40 magnification) of Fos (green) and PNMT (red) immunolabeling in the C1 medullary region of rat tissue (n  4 animals/group). Cy3
fluorescence is pseudocolored red, and Alexa Fluor 488 is represented in green. Images represent staining in control (A), single-hypoglycemia (hypo) (B),
repeated-hypo (C), hypo prevention (D), and naloxone-treated (E) animal tissue. Overlapping FosPNMT cells are indicated by arrows.
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question of the importance of C1 and C3 neuronal activation in
restoring the counterregulatory response to hypoglycemia in
HAAF remains unanswered by the present study. Additional
approaches targeting restoration of C1 and C3 neuronal acti-
vation, including optogenetic activation of C1 and/or C3 neu-
rons and longer hypoglycemia avoidance time frames, are
required to clarify the relative importance of C1 and C3
neurons as potential therapeutic targets for improving the
counterregulatory epinephrine response in HAAF. Without
data showing that the restoration of C1 and/or C3 neuronal
activation also restores the sympatho-adrenomedullary re-
sponse, the defective counterregulatory response to repeated
hypoglycemia could potentially be due to changes or adapta-
tions occurring in other brain regions, such as those located in
the ventromedial nucleus, arcuate nucleus, and the lateral
hypothalamus.
The mechanism whereby hypoglycemia prevention restores
the sympathoadrenal response in HAAF remains unknown
(11). The present study tested two treatments for HAAF to
determine the physiological underpinnings that appear to re-
verse the phenomenon. The reversibility of HAAF by hypo-
glycemia prevention bears resemblance to the detoxification
processes used to reverse opioid dependence (26, 55). Shifting
of the hypoglycemia counterregulatory response to occur at
lower BG levels can also be likened to the development of
hypoglycemia tolerance. 	-Endorphin is a highly selective
endogenous agonist of -opioid receptors, and its levels are
elevated in both plasma and cerebrospinal fluid after hypogly-
cemia (39, 43). Both C1 and non-C1 neurons in the ventrolat-
eral medulla contain -opioid receptor-immunoreactive synap-
tic inputs that reduce neuronal efferent signaling upon activa-
tion (1, 2, 17, 18, 33, 36). Recently, we also showed that the
selective activation of -opioid receptors in the rostral ventro-
lateral medulla attenuates adrenal sympathetic outflow by
~50% and completely blocks the counterregulatory response to
glucoprivation (22). To the best of our knowledge, it remains
Fig. 5. Representative images (20) of treated C3 sections depicting Fos and phenylethanolamine-N-methyltransferase (PNMT) immunolabeling. A–E:
representative photomicrographs (20 magnification) of Fos (green) and PNMT (red) immunolabeling in the C3 medullary region of rat tissue (n  4
animals/group). Cy3 fluorescence is pseudocolored red, and Alexa Fluor 488 is represented in green. Images represent staining in control (A), single-
hypoglycemia (hypo) (B), repeated-hypo (C), hypo prevention (D), and naloxone-treated (E) animal tissue. Overlapping FosPNMT cells are indicated by
arrows. F: bregma levels used for analysis. AmbC, ambiguus nucleus, compact part; Bo, Bötzinger complex; Sp5, spinal trigeminal nucleus; 4V, fourth ventricle.
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unknown whether C3 neurons also contain -opioid receptor-
immunoreactive synaptic inputs. Activation of -opioid recep-
tors results in protein kinase C-mediated activation of N-meth-
yl-D-aspartate (NMDA) receptors, which are implicated in
tolerance, dependence, and inhibition of neural pathways
(55). Furthermore, the NMDA receptor antagonist MK-801
inhibits the development of tolerance to the analgesic prop-
erties of morphine (30, 55, 56). These data suggest that the
complete reversibility of HAAF after 3 mo may be due to an
NMDA receptor-dependent adaptive alteration in the central
pathways following -opioid receptor activation during hy-
poglycemia (11).
Although it would be of interest to determine whether or not
Fos expression in the C1 cells is uniformly reduced after
repeated bouts of hypoglycemia, the tissue analyzed in the
present study was from the rostral portion of the C1 column,
from bregma level 12.48 mm to 12.24 mm. The C1 cell
column extends from bregma level 13.72 mm to 11.4 mm,
with the bulbospinal component of the rostral C1 cell column
residing between 13.0 mm and 11.4 mm (16). The rostral
C1 neurons that selectively target the intermediolateral cell
column of the spinal cord were of particular interest to us given
that this proportion of C1 cells activate adrenal sympathetic
preganglionic neurons, regulating downstream epinephrine re-
lease (34, 35, 44, 45). This does not discount the possibility
that caudal C1 neurons projecting to the medial hypothalamus
(paraventricular and arcuate nucleus) are also contributing to
the downstream epinephrine response; however, the activation
of caudal C1 cells is more closely linked to behavioral re-
sponses such as feeding following insulin-induced hypoglyce-
mia (10, 44, 54, 61). Furthermore, Senthilkumaran et al. (49)
showed that both caudal and rostral C1 cells are activated after
insulin-induced hypoglycemia, so it would not be surprising if
repeated hypoglycemia also reduced the activation of caudal
C1 neurons, since the behavioral response to hypoglycemia
(i.e., feeding) is reduced in HAAF (47). The present study falls
short in providing an answer for what the relative contribution
of caudal C1 neuronal activation is in terms of hypoglycemia-
induced epinephrine secretion.
Technical limitations. In hypoglycemia, common signs and
symptoms in humans include hunger, shakiness, tachycardia,
dizziness, and sweatiness. We were unable to determine
whether or not there were any of these changes in our con-
scious rodent model of HAAF. These findings highlight a key
limitation in using this approach for modeling HAAF and
awareness of hypoglycemia. Nonetheless, studying physiolog-
ical mechanisms in animals is an invaluable resource that
allows for a deeper understanding of the neuroendocrine mech-
anisms that define HAAF. Future studies should direct atten-
tion toward inducing HAAF in various rodent models of
insulin-dependent diabetes mellitus (streptozotocin-induced
T1D and obese Zucker). Longer hypoglycemia prevention
protocols should also be considered despite the healthy/nondi-
abetic background of the animals.
In conclusion, the present study utilized immunohistochem-
ical and biochemical techniques to show that the activation of
C1 and C3 medullary neurons is impaired in a rodent model of
HAAF. These reductions in neuronal activation contribute to
the attenuated plasma epinephrine release in HAAF. Neither 1
wk of hypoglycemia prevention nor the injection of naloxone
during antecedent hypoglycemia restored the activation of C1
and C3 neurons or the plasma epinephrine response. The
present study highlights that the responsiveness of glucoregu-
Fig. 6. Representative images (40) of treated C3 sections depicting Fos and phenylethanolamine-N-methyltransferase (PNMT) immunolabeling: representative
photomicrographs (40 magnification) of Fos and PNMT immunolabeling in the C3 medullary region of rat tissue (n  4 animals/group). Cy3 fluorescence is
pseudocolored red, and Alexa Fluor 488 is represented in green. Images represent staining in control (A), single-hypoglycemia (hypo) (B), repeated-hypo (C),
hypo prevention (D), and naloxone-treated (E) animal tissue. Overlapping FosPNMT cells are indicated by arrows.
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latory C1 and C3 neurons is critical and must be considered
when testing suitable therapies for HAAF.
Perspectives and significance. Sympathoadrenal responsive-
ness can be measured both subjectively (neuroglycopenic and
neurogenic symptoms) and objectively (hormone release) in
humans. However, to achieve a greater mechanistic under-
standing of HAAF, an integrative physiological approach in
experimental models of HAAF is required. Our study is the
first to report a direct relationship between reduced glucose
responsiveness in ventrolateral and dorsomedial medullary
neurons leading to sympathoadrenal failure in a rodent model
of HAAF. Additional experiments modeling HAAF on a T1D
background and successfully restoring the activation of glu-
cose-responsive C1 and C3 neurons are required. This will
determine the relevance of C1 and C3 neurons in restoring the
impaired sympathoadrenal response to hypoglycemia in
HAAF.Fig. 7. Antecedent insulin-induced hypoglycemia reduces activation of adren-
ergic neurons in medullary C1 and C3 nuclei after subsequent hypoglycemia:
neuronal activation represented by double-stained Fos phenylethanolamine-
N-methyltransferase (PNMT) neurons expressed as % of total PNMT
neurons in the C1 (A) and C3 (B) regions (n  4 animals/group). The ratio of
activated catecholaminergic neurons in both regions was significantly higher in
the single-hypoglycemia (hypo) group compared with the repeated-hypo
group. There was no recovery in C1 or C3 neuronal activation after hypo
prevention or naloxone treatment. Data are means  SE. Statistical signifi-
cance was determined by 1-way ANOVA and multiple-comparison analysis
with a Holm-Šidák correction. *P  0.05, **P  0.01, ***P  0.001,
****P  0.0001, significantly different from all other groups.
Fig. 8. Correlation between plasma epinephrine levels and C1 and C3 neuronal
activity: positive correlation between plasma epinephrine levels and the degree
of C1 (A) and C3 (B) neuronal activation after hypoglycemia. Statistical
significance was determined by a Pearson correlation test with GraphPad Prism
software. PNMT, phenylethanolamine-N-methyltransferase.
Fig. 9. Repeated hypoglycemia (hypo) does not alter neuronal phenylethano-
lamine-N-methyltransferase (PNMT) expression in the medullary C1 and C3
regions: neuronal cell counts depicting the total number of PNMT neurons in
both the C1 and C3 regions (n  4 animals/group). The total number of
adrenergic neurons in the C1 and C3 regions did not vary between groups. Data
are means  SE. Statistical significance was determined by 2-way ANOVA.
P 
 0.05, not significantly different from all other groups.
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